Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Enoch Cobbina"'
Autor:
Bo Zheng, Lucia Wille, Karsten Peppel, David Hagen, Andrew Matteson, Jeffrey Ahlers, James Schaff, Fei Hua, Theresa Yuraszeck, Enoch Cobbina, Joshua F. Apgar, John M. Burke, John Roberts, Raibatak Das
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 7, Pp 696-708 (2021)
Abstract We developed a mathematical model for autologous stem cell therapy to cure sickle cell disease (SCD). Experimental therapies using this approach seek to engraft stem cells containing a curative gene. These stem cells are expected to produce
Externí odkaz:
https://doaj.org/article/8ba72c23733b4ce5b2853ef6f3a3f586
Autor:
Lucia Wille, Enoch Cobbina, Raibatak Das, John M. Burke, Karsten Peppel, Andrew Matteson, David Robert Hagen, Joshua F. Apgar, John Roberts, Fei Hua, Theresa Yuraszeck, James Schaff, Bo Zheng, Jeffrey Ahlers
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 7, Pp 696-708 (2021)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology
We developed a mathematical model for autologous stem cell therapy to cure sickle cell disease (SCD). Experimental therapies using this approach seek to engraft stem cells containing a curative gene. These stem cells are expected to produce a lifelon
Autor:
Zhi-Bing You, Enoch Cobbina, Aaron Hammer, Sara L. Deschaine, Kelly M. Abshire, Mehdi Farokhnia, Mary R. Lee, Fatemeh Akhlaghi, Anitha Saravanakumar, Lorenzo Leggio, Carolina L. Haass-Koffler
Publikováno v:
Int J Neuropsychopharmacol
Background Accumulating evidence has established a role for the orexigenic hormone ghrelin in alcohol-seeking behaviors. Accordingly, the ghrelin system may represent a potential pharmacotherapeutic target for alcohol use disorder. Ghrelin modulates
Publikováno v:
Clin Pharmacokinet
The ghrelin receptor (GHS-R1a) is a potential target for alcohol use disorders. PF-5190457 is the first inverse agonist of GHS-R1a to progress to clinical development with potential to treat alcohol use disorder. We present a population pharmacokinet
Autor:
April N. Le, Lorenzo Leggio, Lisa A. Farinelli, Enoch Cobbina, Jenica D. Tapocik, Fatemeh Akhlaghi, Mwlod Ghareeb, Mehdi Farokhnia, Alexandra A. Dias, Markus Heilig, Mary R. Lee, Melanie L. Schwandt, Sofia Bouhlal
Publikováno v:
Molecular psychiatry
Rodent studies indicate that ghrelin receptor blockade reduces alcohol consumption. However, no ghrelin receptor blockers have been administered to heavy alcohol drinking individuals. Therefore, we evaluated the safety, tolerability, pharmacokinetic
Autor:
Fatemeh Akhlaghi, Enoch Cobbina, Xiaobai Li, Anitha Saravanakumar, Jillian T. Battista, Lisa A. Farinelli, Mehdi Farokhnia, Mary R. Lee, Lorenzo Leggio
Publikováno v:
Neuropharmacology
Both animal and human work suggests that the ghrelin system may be involved in the mechanisms that regulate the development and maintenance of alcohol use disorder. Previously, in a Phase 1b study, we tested pharmacological blockade of the growth hor
Autor:
Isabel Tomaz, João Costa Pessoa, Sameena Mehtab, Eva Enyedi, Isabel Cavaco, Tamás Kiss, Isabel Correia, Gisela Gonçalves, Tamás Jakusch, Enoch Cobbina
Publikováno v:
Journal of the Mexican Chemical Society. 57
In this work the binding of VIVO2+ and VIVO-complexes to serum albumins {human serum albumin (HSA), bovine serum albumin (BSA) and porcine serum albumin (PSA)} are studied using circular dichroism (CD), electron paramagnetic resonance (EPR) and visib
Autor:
Enoch Cobbina, Fatemeh Akhlaghi
Publikováno v:
Drug metabolism reviews. 49(2)
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver disorders. It is defined by the presence of steatosis in more than 5% of hepatocytes with little or no alcohol consumption. Insulin resistance, the metabolic syndrome or type 2 diabetes